In short, 20 minute sessions, we held interactive conversation where participants could ask the questions that matter — how powerful, practical, and portable ERG technology can help you diagnose and manage diabetic retinopathy, glaucoma, and more.
Dr. Ferrucci is both Chief of Optometry as well as Residency Director at the Sepulveda VA Ambulatory Care Center and Nursing Home. He is also an Assistant Professor at the Southern California College of Optometry.
His emphasis includes therapeutic treatment of glaucoma, cataracts, diabetic retinopathy, and posterior segment disease. He also performs on-site fluorescein angiography, including injections and digital imaging.
Dr. Ferrucci has lectured extensively, with a special interest in Diabetes, Diabetic Eye Disease and Fluorescein Angiography. He has also published several articles in optometric journals, including The New England Journal of Optometry , Optometry and Vision Science, and Optometry: Journal of The AOA. He is an active member in the American Optometric Association and the National VA Optometric Association, as well as a fellow in both the American Academy of Optometry and the Optometric Retinal Society. He is currently President of the San Fernando Valley Optometric Society, and a consultant for the Accreditation Council on Optometric Education.
Dr. Justin Schweitzer specializes in advanced glaucoma, refractive surgical clinical care, and anterior segment pathology at Vance Thompson Vision. He received his professional training and Doctor of Optometry degree from Pacific University College of Optometry in Forest Grove, OR.
In 2012, he pursued his dream to focus on glaucoma, advanced anterior segment surgery care and pathology, joining Vance Thompson Vision in Sioux Falls, South Dakota. He earned Fellowship in the American Academy of Optometry in 2013, is the Optometric Externship Director at Vance Thompson Vision, and Adjunct Clinical Professor of the Illinois College of Optometry and Kentucky College of Optometry.
An Adjunct Clinical Professor at the Illinois College of Optometry, Dr. Schweitzer regularly lectures on glaucoma, anterior segment pathology, refractive surgical clinical care, and surgical management at state, regional, and national meetings. He is currently the Chief Medical Editor for Modern Optometry and has contributed book chapters, journal articles, and case studies in peer-reviewed and non-peer-reviewed journals including Review of Optometry, Optometry Times, Primary Care Optometry News, Optometric Management, The Journal of Cataract and Refractive Surgery, Clinical Ophthalmology, and The Journal of Glaucoma. He has research interests in minimally invasive glaucoma surgery and biomechanical properties of the cornea as it relates to glaucoma.
Dr. Schweitzer is an advocate of an integrated eye care delivery model and is currently serving as a board member for the South Dakota Optometric Society. He also serves as a board member of the Optometric Glaucoma Society, a member of the American Optometric Association; Optometric Cornea, Cataract, and Refractive Society; Scleral Lens Education Society; Intrepid Eye Society; and is actively involved in his community’s eye care initiatives.
Warning: This product can expose you to chemicals including lead, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.
Substance Tables:
The table below lists substances which may be contained within LKC’s RETeval and RETevet products. Substances listed as Type 1 are within permissible levels in one or more of LKC’s products. Substances listed as Type 2 are used in the production of some components used in LKC products and may be present at trace levels, but are typically destroyed during processing.
RETeval and RETevet Devices
| Substance | CAS # | Type | Listed as causing: |
| Nickel | 7440-02-0 | 1 | Cancer |
| Acrylonitrile | 107-13-1 | 2 | |
| Ethylbenzine | 100-41-4 | 2 | |
| Crystaline Silica | 14808-60-7 | 1 | |
| Lead | 7439-92-1 | 1 | Cancer Developmental Toxicity Male Reproductive Toxicity Female Reproductive Toxicity |
| Methylene Chloride | 75-09-2 | 2 | Cancer Female Reproductive Toxicity |
| Bisphenol A | 80-05-7 | 2 | |
| N-Hexane | 110-54-3 | 2 | Male Reproductive Toxicity |
